What is Alzamend Neuro Financial Strength?
Alzamend Neuro has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Alzamend Neuro did not have earnings to cover the interest expense.
As of today, Alzamend Neuro's Altman Z-Score is 0.00.
Competitive Comparison of Alzamend Neuro's Financial Strength
For the Biotechnology subindustry, Alzamend Neuro's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Financial Strength distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's Financial Strength falls into.
Alzamend Neuro Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Alzamend Neuro's Interest Expense for the
months ended in Jan. 2024 was $-0.00 Mil. Its Operating Income for the
months ended in Jan. 2024 was $-2.66 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.00 Mil.
Alzamend Neuro's Interest Coverage for the quarter that ended in Jan. 2024 is
| Alzamend Neuro did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Alzamend Neuro's Debt to Revenue Ratio for the quarter that ended in Jan. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Alzamend Neuro has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (Alzamend Neuro) Business Description
Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
| Ault Milton C Iii |
10 percent owner |
11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141 |
| David J Katzoff |
officer: Chief Operating Officer |
201 SHIPYARD WAY, NEWPORT BEACH CA 92663 |
| Stephan Jackman |
director, officer: Chief Executive Officer |
C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
| Lynne Fahey Mcgrath |
director |
28145 CEDAR POINT RD., EASTON MD 21601 |
| Mark Gustafson |
director |
10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9 |
| William B. Horne |
director |
C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626 |
| Henry Carl Nisser |
director, officer: Exec VP and General Counsel |
100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017 |
| Kenneth S Cragun |
officer: SVP of Finance |
3775 CHIPPEWA CIRCLE, CORONA CA 92881 |
| Jeffrey Oram |
director |
15 ORCHARD STREET, MENDHAM NJ 07945 |
| Escalona Lien |
officer: Chief Financial Officer |
C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
| Andrew H. Woo |
director |
2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALZN has been successfully added to your